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Abstract
Under US Public Health Service guidelines, organ donors with risk factors for human 
immunodeficiency virus (HIV), hepatitis B virus (HBV), or hepatitis C virus (HCV) are 
categorized as increased risk donors (IRD). Previous studies have suggested that IRD organs are 
utilized at lower rates than organs from standard risk donors (SRD), but these studies were 
conducted prior to universal donor nucleic acid test screening. We conducted risk-adjusted 
analyses to determine the effect of IRD designation on organ utilization using 2010–2017 data (21 
626 heart, 101 160 kidney, 52 714 liver, and 16 219 lung recipients in the United States) from the 
Organ Procurement and Transplantation Network. There was no significant difference (P < .05) 
between risk-adjusted utilization rates for IRD vs SRD organs for adult hearts and livers and 
pediatric kidneys, livers, and lungs. Significantly lower utilization was found among IRD adult 
kidneys, lungs, and pediatric hearts. Analysis of the proportion of transplanted organs recovered 
from IRD by facility suggests that a subset of facilities contribute to the underutilization of adult 
IRD kidneys. Along with revised criteria and nomenclature to identify donors with HIV, HBV, or 
HCV risk factors, educational efforts to standardize informed consent discussions might improve 
organ utilization.
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1 | INTRODUCTION
Since the emergence of the human immunodeficiency virus (HIV) epidemic, the US Public 
Health Service (PHS) has made recommendations to reduce the risk of HIV transmission 
associated with organ transplantation.1–3 Historically, these recommendations included 
strategies to identify HIV-related risk factors among donors based in part on characteristics 
that have been recognized to be associated with transmission to recipients.3 
Recommendations also included laboratory testing of donors initially to detect anti-HIV 
antibodies, with additional testing added as technologies such as nucleic acid testing (NAT) 
have been developed.1 In 2013, based on transplant-related transmission events and reports 
of poor recipient outcome from hepatitis B (HBV) and C (HCV) transmission, the PHS 
released a revised guideline to reduce the risk of unintended HIV, HBV, and HCV 
transmission through transplantation.1 These recommendations were enhanced by 
recommending specific recipient informed consent, expanded donor HCV (anti-HCV 
antibody and NAT) and HBV (surface antigen and core antibody) laboratory screening, and 
recipient monitoring for evidence of disease transmission. The recommendations were not 
intended to restrict transplantation but to facilitate appropriate donor laboratory screening, 
enhance informed decision making by recipients, and ensure prompt recognition of donor-
derived disease transmission so treatment could be initiated.
Per the 1994 guideline, organ donors were screened for HIV using serologic testing. Donors 
with risk factors for HIV infection and transmission to recipients were designated “Centers 
for Disease Control and Prevention (CDC) High Risk” donors.3 The 2013 guideline 
modified terminology to “Increased Risk Donor (IRD)” and recommended HCV NAT for all 
donors and HIV NAT or p24 antigen testing for IRD.1 “Increased” was adopted over “high” 
to convey the continued, though small, possibility of donor-derived disease transmission 
despite NAT. As a result of the opioid epidemic, the proportion of the donor population that 
is categorized as IRD has increased.4 IRD has a higher prevalence of HBV and HCV 
infection in comparison with standard risk donors (SRD).4 Several studies have reported 
underutilization of organs from IRD, but have methodological limitations that reduce the 
relevance of previous estimates of underutilization for current decision making. The most 
substantial limitations of previous studies were inadequate control for donor HCV serostatus 
and the use of limited risk adjustment models5,6 as well as other limitations such as the 
exclusion of extended criteria donors (ECD) or organs recovered after cardiac death,5 and 
older study time-frames.5,7 Understanding the impact of IRD designation on organ 
utilization is important. Studies have shown that patients awaiting transplantation who 
decline IRD organs have increased mortality compared to patients who accept IRD organs.
6,8
 Additionally, effective therapies are available for HIV, HBV, and HCV.
To determine whether IRD categorization is associated with decreased utilization of organs, 
we analyzed data obtained from the Organ Procurement and Transplantation Network 
(OPTN).* We developed separate risk adjustment models for adult and pediatric heart, 
kidney, liver, and lungs and tested for a relationship between IRD categorization and 
underutilization after accounting for these risk adjustment factors, first with all donors, then 
*https://optn.transplant.hrsa.gov/
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with HBV and HCV NAT and/or serology-positive donors removed. These donors were 
removed because, while a large numbers of HBV and HCV NAT or antibody-positive donors 
are designated IRD, per the 2013 guideline, use of these organs is characterized as 
potentially resulting in expected donor-derived infection.1 Decisions to accept or decline 
these organs are more likely to be due to the test results rather than donor IRD status. In 
addition to quantifying utilization, we further examined utilization by region and organ type. 
CDC, Health Resources and Service Administration (HRSA), and other federal partners are 
currently considering revisions to the 2013 guideline recommendations. Utilization effects 
described are further discussed in context of future guideline recommendation revisions.
2 | METHODS
Data reported by US organ procurement organizations and transplant centers to the OPTN 
from January 1, 2010-December 31, 2017 were analyzed. Transplant procedures were 
identified for adult (age ≥18 years) and pediatric (age <18 years) heart, kidney, liver, and 
lung recipients and were matched to deceased donor records. The OPTN database included 
70 414 deceased donors during 2010–2017, including 4157 deceased donors from whom a 
heart, kidney, liver, or lung was not recovered (ie, pancreas or intestines were recovered 
from these donors). Forty deceased donors whose IRD status was unknown were excluded. 
Transplant and recipient characteristics were obtained for 191 719 total transplants (21 626 
hearts, 52 714 livers, 16 219 lungs, and 101 160 kidneys) performed during this period. 
Simultaneous kidney-pancreas transplants were reclassified as kidney transplants, leading to 
2305 additional kidney transplants. Sixty-two heart-lung transplants were excluded because 
of the small number of recipients of this anatomically intact organ combination. The 
analyses were stratified by organ. Donors designated “CDC High Risk” or “PHS Increased 
Risk” were categorized as IRD for these analyses.
2.1 | Utilization rate calculation
Previously described methods were used for estimating organ utilization rate.5,7 Utilization 
estimate rates were calculated with individual recipient transplant surgery as the numerator 
and potential donors as the denominator. For heart utilization, only a single donor can be 
associated with a single recipient. However, for liver, lungs, and kidneys, a single donor can 
be associated with multiple recipients. To ensure that lung and liver donors are not counted 
twice, lungs or livers from a single donor that were transplanted to either 2 adult or 2 
pediatric recipients were excluded. Because pediatric and adult recipients were examined 
separately, lungs and livers from a single donor that were transplanted to 1 adult and 1 
pediatric recipient were retained for the analysis. Each deceased donor was assumed to have 
2 kidneys that can be recovered for transplant, and each donor is therefore duplicated in the 
denominator of the utilization rate. En-bloc or sequential kidney transplants were counted as 
a single organ.
The accuracy of the utilization rate estimation is dependent on correctly matching the 
denominator to the recipient population. Because adult heart, kidney, liver, and lung 
recipients were most likely to receive an organ from a donor aged >15 years (Figure S1), the 
adult utilization rate was calculated based on donors aged >15 years. Pediatric heart, liver, 
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and lung recipients are most likely to receive an organ from donors aged <21 years, but most 
pediatric kidney recipients received organs from donors aged 12–35 years. The pediatric 
utilization rate was calculated using donors aged <21 years and a sensitivity analysis using 
donors aged 12–35 years was performed.
2.2 | Risk adjustment models
Risk adjustment models to adjust for the association between donor characteristics and organ 
transplant were developed using logistic regression with stepwise model selection. 
Transplants that occurred between January 1, 2014 and December 31, 2017 were used to fit 
the risk adjustment models. Risk adjustment variables (Table S1) were identified from the 
deceased donor database using variables based on the Scientific Registry of Transplant 
Recipients posttransplant outcomes models.9 A risk adjustment model was obtained 
separately for each organ, stratified by age with entry and stay P values set to .2 and .05, 
respectively (Table 1, Tables S2–S9). An additional 2-level time-period variable (2010–2013 
or 2014–2017) was used to compare utilization before and after the 2013 PHS Guideline 
publication.1 This time-period main effect represents changes in overall utilization (IRD and 
SRD combined), and the interaction between time period and IRD status represents 
differential changes for IRD compared to SRD organs associated with the PHS Guideline 
revision made in 2013.1
Because kidney donors were duplicated in the denominator when calculating utilization 
rates, the fit of the risk adjustment model was tested using a generalized estimating equation 
(GEE) approach to account for donor duplication.10 All parameters in the risk adjustment 
model for adult kidneys were found to be statistically significant when the 0047EE model 
was used.
The risk-adjusted utilization rate for IRD (SRD) organs was calculated by multiplying the 
observed overall utilization rate (independent of IRD status) by the ratio of the utilization 
rates predicted from the null model for IRD (SRD) and the risk-adjusted utilization rate for 
IRD (SRD) donors. The risk-adjusted logistic regression model was used to test for 
differences between IRD and SRD rates. Finally, the model was used to predict the number 
of underutilized IRD organs (ie, the number of organs not utilized as result of IRD 
categorization), calculated as the difference between the predicted number of transplanted 
organs under the fitted model and the model with the IRD parameter set to zero.6 Because 
including donor HBV/HCV test result (antibody and/or NAT) status as part of a logistic 
regression model might not appropriately control the potentially complex relationship 
between donor HBV/HCV status, IRD status, and organ utilization, the utilization rate 
analyses were repeated after excluding donors with positive test results for HBV or HCV 
(antibody and/or NAT).
2.3 | Center-level model
Additional analyses were conducted to determine whether statistically different proportions 
of IRD organs transplanted in each facility (also referred to as transplant center) compared 
with the OPTN regional rate (ie, the expected rate) could drive underutilization estimates 
nationally. For these analyses, a binomial distribution was assumed for each transplant 
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center, j, with parameters nj and p, where nj is the number of transplants in facility j and p is 
the proportion of IRD organs transplanted in the OPTN region corresponding to facility j. 
The binomial cumulative distribution function was used to obtain the probability that any 
randomly observed IRD organ proportion could be less than or equal to the observed facility 
proportion, under the null hypothesis that the center does not underutilize IRD organs. 
Under the null hypothesis (ie, facility utilizes IRD organs at the regional rate), 2.5% of 
transplant centers would be expected to have a probability ≤.025. If the proportion of centers 
<0.025 (or ≥0.975) is more than expected under the null hypothesis, this suggests 
underutilization (or overutilization) of IRD organs.
All analyses were performed using SAS software, version 9.4 (SAS Institute Inc., Cary, 
NC).
3 | RESULTS
3.1 | IRD and SRD organ utilization rates
Between January 1, 2010 and December 31, 2017, 21 626 heart transplants (18 368 to adult 
recipients and 3258 to pediatric recipients) were reported to OPTN (Figure 1). There were 
52 714 liver transplants (48 770 to adult recipients, 3944 to pediatric recipients), most of 
which were transplanted as a whole liver to a single recipient. A segmented liver from a 
single donor was transplanted to 2 adult recipients in 58 cases and to 2 pediatric recipients in 
98 cases, which were excluded to avoid double-counting donors. The 513 segmented livers 
that were transplanted to 1 pediatric recipient and 1 adult recipient were included in the 
analysis. The majority of the 16 219 lung transplants (15 835 to adult recipients; 384 to 
pediatric recipients) involved a single donor with a single recipient, although 2490 lungs 
from 1245 donors were transplanted to 2 different recipients. Of these, lungs from 543 
donors to 1086 adult recipients were each transplanted at the same center and were excluded 
to avoid being counted twice.
There were 101 160 total kidney transplants (97 343 adult recipients; 3817 pediatric 
recipients), which included 2422 recipients (2363 adult recipients; 59 pediatric recipients) 
who received both kidneys from a single donor, either en-bloc or sequentially, and were 
therefore counted as a single event for the numerator and the denominator.
Table 1 shows the risk adjustment models for the outcome event of heart, kidney, liver, or 
lung transplant, fit separately for adult and pediatric recipients. The full models for each 
organ (adult and pediatric), including estimates, odds ratios, and P values are presented in 
Tables S2–S9. Unadjusted utilization rates are significantly lower (P < .05) for all IRD 
organs (adult and pediatric) compared to the utilization rates of the corresponding SRD 
organs, except IRD adult hearts and livers, which had higher utilization rates compared to 
SRD adult hearts and livers (Table 2). After initial risk adjustment, and including HBV- and 
HCV-positive donors in the model, the utilization rates were significantly lower (P < .05) for 
IRD adult kidneys, hearts, and lungs and IRD pediatric kidneys and hearts transplanted 
during both time periods and for IRD pediatric livers and lungs transplanted during 2010–
2013, compared to the utilization rates of the corresponding SRD organ. There was no 
significant difference (P < .05) between the risk-adjusted utilization rates of adult livers 
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transplanted during both time periods and pediatric livers and lungs transplanted during 
2014–2017 from IRD and SRD donors. The estimated number of underutilized organs per 
year was higher for 2014–2017 compared to 2010–2013, except for adult hearts and 
pediatric livers and lungs. The results for pediatric kidneys did not change when the 
inclusion criteria for donors was changed from <21 years to 21–35 years.
The proportion of SRD and IRD donors that were HBV or HCV positive was 6.2% and 
23.5%, respectively. After excluding donors with positive test results for HBV or HCV, the 
risk-adjusted utilization rates were significantly lower (P < .05) for IRD adult kidneys and 
lungs and IRD pediatric kidneys and hearts, compared to the utilization rates of the 
corresponding SRD organ (Table 3). There was no significant difference (P < .05) between 
the risk-adjusted utilization rates of adult hearts and livers and pediatric kidneys, livers, and 
lungs transplanted. The estimated annual underutilization of organs due to IRD designation 
was 148 adult kidneys, 34 adult lungs, and 12 pediatric hearts.
The 8 risk-adjusted statistical models were also run for 2010–2017 excluding HBV- and 
HCV-positive donors and with the addition of a time-period variable (2010–2013 or 2014–
2017) and the interaction between time period and IRD status. The interaction between time 
period and IRD status was significant for adult heart (P < .001), liver (P < .001), and lung (P 
< .001), with each showing an incremental increase in utilization rate from IRD donors 
compared to the utilization rate from SRD donors from 2010–2013 to 2014–2017.
3.2 | Transplant center level use of IRD organs
The proportion of transplants that involved an IRD organ varied by region (Figure 2). 
Additionally, the proportion of IRD organs transplanted among all transplants varied widely, 
by center, within each region. Table 4 shows the number of facilities that were below the .
025 and above the .975 cumulative probability of their binomial distribution. The number of 
adult facilities below the .025 cumulative binomial distribution probability was higher than 
expected (2.5%) for hearts, kidneys, and livers (Table 4). For kidneys, 19.7% of adult 
facilities had a probability of <.025, suggesting these facilities underutilized IRD kidneys. 
Hearts and livers also show underutilizing centers, although fewer centers transplant hearts 
(N = 106) and livers (N = 118) compared to those that transplant kidneys (N = 208). The 
number of lung transplant centers below the 0.025 threshold was consistent with the 
expected proportion.
4 | DISCUSSION
Previous studies concluded that there was evidence for underutilization of hearts, kidneys, 
livers, and lungs in both adult and pediatric patients.5–7 Our updated analyses demonstrate 
that with statistical adjustment for variables that may affect organ utilization, and with the 
exclusion of HBV- and HCV-positive donors, there is no significant difference between 
utilization of most organs recovered from IRD or SRD donors with the exception of 3 organ 
types. Furthermore, IRD utilization of most organ types increased compared to SRD 
utilization in the 4-year period after the 2013 changes to the PHS guidelines, suggesting that 
changes to the guidelines may have resulted in increased utilization of IRD organs. Between 
2014 and 2017, there was underutilization of adult kidneys and lungs and pediatric hearts 
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recovered from IRD compared with SRD. The underutilization of adult kidneys from IRD 
donors appears to be attributable to low use by a subset of centers, rather than a broader 
underutilization across all transplant programs in the United States (Table 5). The 
underutilization of lungs from IRD donors appears to be more uniformly distributed across 
programs. We estimate that fewer than 200 kidneys or lungs are underutilized annually due 
to donor increased risk status, below previous estimates.5 While efforts to improve the use of 
IRD kidneys and lungs may modestly increase the number of these transplants in the United 
States, additional interventions are necessary in order to bridge the gap between the numbers 
of organs needed and available for patients awaiting transplantation.†
These analyses highlight the importance of risk adjustment when estimating utilization rates 
from IRD and SRD organs. A previous analysis examining IRD kidney use adjusted for 12 
variables.7 A different study analyzing underutilization of hearts, kidneys, livers, and lungs 
used a 4-variable risk adjustment model and excluded donation after cardiac death (DCD) 
donors and ECD5 and estimated more underutilization than the present study, likely due to 
the more comprehensive risk adjustment performed in the present study. Several factors 
might be associated with a recipient or program declining an IRD organ. The “increased risk 
donor” terminology might result in patient apprehension regarding organ quality or the risk 
of disease transmission.5,7,11 Poorer outcomes, including recipient death or graft failure, 
have previously been attributed to HIV or HCV transmission through transplantation.12,13 
However, effective therapies for HIV, HBV, and HCV are now available with improved 
outcomes in the setting of transplantation.14 While we did not evaluate wait times or match 
efficiency as part of the present study, the lower utilization of IRD lungs observed in the 
present study might be a result of the higher availability of lungs relative to the number of 
candidates awaiting transplant, compared to other organs.1 Because patients waiting for 
kidney transplants have effective bridge therapies such as hemodialysis and peritoneal 
dialysis, they might be more inclined to decline an IRD organ compared to patients waiting 
for liver or lung transplants.
While previous studies have suggested underutilization of hearts from IRD donors,5–7 we 
did not observe a statistically significant effect after controlling for HBV- or HCV-positive 
donor test results. A large proportion of donors with NAT or serologic evidence of HBV or 
HCV are further designated as IRD (23.5% IRD; 6.2% SRD) as a result of risk behaviors 
that predispose them to other infections, such as HIV, leading to a potential bias in results 
when these donors are included. The present findings suggest that patients and providers 
might decline IRD organs because the donor has a positive test result for HBV or HCV, 
rather than due to IRD classification.
We observed lower utilization of IRD kidneys in a subset of facilities in the United States, 
suggesting that underutilization of IRD kidneys might be the result of individual transplant 
center practices, rather than broader underutilization. These findings underscore the need for 
improved targeted educational efforts to assist patients and providers when choosing to 
accept or decline IRD organs. Although HIV, HBV, and HCV transmissions through organ 
transplantation have been described, with HBV and HCV transmissions reported since the 
†https://optn.transplant.hrsa.gov/data/view-data-reports/
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implementation of the 2013 guideline, the risk of transmission is low. Enhanced educational 
materials and interventions targeted for other aspects of transplantation to improve organ 
utilization have been described.15–17 Development of standardized educational materials that 
present available evidence regarding transmission risk and outcomes may enhance IRD-
related informed consent discussions between clinicians and patients and increase organ 
utilization.‡
These findings are subject to the following limitations. The eligible donor population used 
for these analyses only included individuals from whom at least 1 organ was recovered. 
Individuals considered for organ donation but from whom an organ was not recovered were 
not included. The impact on the utilization effects presented here cannot be quantified. The 
risk adjustment model was based on variables available in the OPTN database. However, 
additional factors that are not entered in the OPTN database might also impact utilization. 
The modeling approach included only main effects, and it is possible that some of the 
included variables (such as DCD and ECD, which have been excluded in previous analyses5) 
require a more complex parameterization in the statistical model (eg, interactions). However, 
in sensitivity analyses, excluding DCD donors and ECD did not change the results.
Although the present findings suggest underutilization of IRD organs, the magnitude of 
underutilization is less than previously described.5,7 Given the morbidity and mortality 
among patients awaiting transplantation, any efforts to improve organ utilization is a public 
health priority. CDC, HRSA, and other federal partners are considering revisions to the 2013 
PHS guideline recommendations to improve organ acceptance and to reflect advances in 
transplant-related safety interventions such as NAT, with results available pretransplant. In 
2019, the Advisory Committee on Blood and Tissue Safety and Availability will consider the 
findings of the present study when considering changes to current guideline 
recommendations. Considerations include reassessment of the term “increased risk,” which 
might be currently contributing to underutilization.5 Revisions to the recommendations will 
be accompanied by efforts to develop standardized educational material to improve the 
informed consent process, in order to improve utilization. While these efforts are warranted, 
interventions to prevent and treat end-organ disease are necessary. Additionally, efforts to 
increase organ donation are necessary to reduce morbidity and mortality among patients 
with end-stage organ disease.
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FIGURE 1. 
Diagram showing data used in the utilization analyses. IRD, increased risk donors; OPTN, 
Organ Procurement and Transplantation Network
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FIGURE 2. 
Boxplots of facility–level proportion of transplants that involved an increased risk donor 
(IRD) organ by Organ Procurement and Transplantation (OPTN) region and organ. For each 
bar, the box extends between the 25th (Q1) and 75th (Q3) percentiles and the line in the 
middle of the box represents the median; the horizontal lines extend to the minimum (Min) 
and maximum (Max), excluding outliers that are plotted as unfilled circles. Low–volume 
facilities are defined as those with <10 transplants for hearts and lungs and <20 transplants 
for kidneys and livers. The boxplots are stratified by the 11 OPTN transplant regions: 
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MI, OH), and Region 11 (KY, NC, SC, TN, southern VA)
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